Search by Drug Name or NDC

    NDC 57894-0111-02 CARVYKTI 100000000 1-Jan Details

    CARVYKTI 100000000 1-Jan

    CARVYKTI is a INTRAVENOUS INJECTION, SUSPENSION in the CELLULAR THERAPY category. It is labeled and distributed by Janssen Biotech, Inc. The primary component is CILTACABTAGENE AUTOLEUCEL.

    Product Information

    NDC 57894-0111
    Product ID 57894-111_0d94e55a-8ea5-c58a-e063-6394a90ada9e
    Associated GPIs 21651025101820
    GCN Sequence Number 083125
    GCN Sequence Number Description ciltacabtagene autoleucel PLAST. BAG 1X10EXP8 INTRAVEN
    HIC3 V35
    HIC3 Description ANTINEOPLASTIC - CAR-T CELL IMMUNOTHERAPY
    GCN 52002
    HICL Sequence Number 047873
    HICL Sequence Number Description CILTACABTAGENE AUTOLEUCEL
    Brand/Generic Brand
    Proprietary Name CARVYKTI
    Proprietary Name Suffix n/a
    Non-Proprietary Name ciltacabtagene autoleucel
    Product Type CELLULAR THERAPY
    Dosage Form INJECTION, SUSPENSION
    Route INTRAVENOUS
    Active Ingredient Strength 100000000
    Active Ingredient Units 1-Jan
    Substance Name CILTACABTAGENE AUTOLEUCEL
    Labeler Name Janssen Biotech, Inc
    Pharmaceutical Class n/a
    DEA Schedule n/a
    Marketing Category BLA
    Application Number BLA125746
    Listing Certified Through 2024-12-31

    Package

    NDC 57894-0111-02 (57894011102)

    NDC Package Code 57894-111-02
    Billing NDC 57894011102
    Package 1 INJECTION, SUSPENSION in 1 BAG (57894-111-02)
    Marketing Start Date 2022-02-28
    NDC Exclude Flag N
    Pricing Information N/A